

Media release

Straumann's new-generation small-diameter soft-tissue-level implant enters full market release

- *New implant offers increased flexibility and additional treatment options*
- *Combines the exceptional strength of Roxolid[®], the fast osseointegration of SLActive[®] and the reliability and improved handling advantages of the CrossFit[®] connection*
- *Full launch in the US, Europe and Australia with other markets¹ to follow*

Phoenix/Basel, 2 March 2012 – At the Academy of Osseointegration's annual meeting in Phoenix (USA), Straumann announced that its new-generation, small-diameter, soft-tissue-level implant is now available to customers in the US, Europe and Australia. The new implant, which is called the 'Straumann[®] Standard Plus Narrow Neck CrossFit[®]' (NNC), is used for tooth replacement in situations, where space or bone is limited. It combines the exceptional strength of Straumann's Roxolid[®] material, the fast osseointegration of the SLActive[®] surface and the reliability and improved handling advantages of Straumann's CrossFit[®] connection.

Beat Spalinger, President & CEO of Straumann, commented:

"This implant is the result of continued innovation, development, and refinement to meet medical needs and customer requirements. NNC brings together all our experience in design, technology, and clinical application, combining new and established features to enhance convenience and open up new treatment possibilities. Although it is a product of progressive development over many years, we chose to introduce it prudently through a controlled market release – in the true Straumann way. Having successfully concluded this phase, we are now making it available on a much wider basis."

Extended treatment options

Small diameter implants are used for limited inter-dental spaces or narrow bone ridges. The NNC is indicated for a variety of uses, including: single-tooth replacement and multiple-tooth replacement with bridges and fixed or removable over-dentures. Being a soft-tissue-level design, the new implant facilitates soft-tissue management and can be placed in a one-step procedure that avoids a second surgical intervention. It is thus designed to simplify treatment and reduces the number of dental visits. The NNC complements Straumann's small-diameter bone-level implant – no other company is able to offer small-diameter implants made of Roxolid for both soft-tissue-level and bone-level applications.

Roxolid is the key

Roxolid has been the key to the development of the NNC. The material's physical strength has enabled Straumann to develop a small diameter implant with an internal rather than an external connection. The implant-abutment interface is designed to provide an excellent seal and distribute the biting pressure optimally. It also offers great flexibility for prosthetic angulation.

The SLActive surface

SLActive is one of the best investigated implant surfaces on the market. A multitude of studies have provided scientific evidence endorsing its remarkable properties^{2,3}



including a marked reduction of healing times³, improved bone formation⁴ and excellent survival rates⁵.

Handling simplicity with the CrossFit connection and new transfer piece

Implant dentistry involves working with tiny, high-precision components in restricted, poorly visible spaces. The CrossFit connection, which is used in Straumann's Bone Level range, is an ingenious solution to this problem because it guides the abutment precisely into the correct position and enables the user literally to 'feel the fit'. In addition to offering a variety of four positions, the CrossFit connection safeguards against abutment rotation.

The NNC implant is complemented by a broad portfolio of surgical and standard prosthetic components. It also features a new convenient transfer piece, which holds the implant in the surgeon's drill and is then easily detached from the implant after insertion in the jawbone.

One system, one instrument set

The NNC supersedes Straumann's existing narrow-neck soft-tissue-level implant, which is made of titanium, has an external hex design, and is only indicated for single-tooth replacement. The new implant has been integrated into Straumann's Dental Implant System which includes a full range of Soft Tissue and Bone Level options and covers all indications⁶. In spite of this, the procedures and instruments are the same and only one surgical kit is required.

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2450 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

E-mail: investor.relations@straumann.com or corporate.communication@straumann.com

Homepage: www.straumann.com

Contacts:

Corporate Communication:

Mark Hill

+41 (0)61 965 13 21

Thomas Konrad

+41 (0)61 965 15 46

Investor Relations:

Fabian Hildbrand

+41 (0)61 965 13 27

Disclaimer

This release contains certain 'forward-looking statements', which can be identified by the use of terminology such as 'to follow', 'will', 'supersedes', or similar wording. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group's products, the potential for the Group's products to become obsolete, the Group's ability to defend its intellectual property, the Group's ability to develop and commercialize new products in a timely manner, the dynamic and competitive environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group's ability to generate revenues and



profitability, and the Group's ability to realize its expansion projects in a timely manner. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.

¹ Pending regulatory approvals/clearances

² Straumann SLActive Scientific Evidence Fifth Edition, 2010

³ Oates TW, Valderrama P, Bischof M, Nedir R, Jones A, Simpson J, Toutenburg H, Cochran DL. Enhanced implant stability with a chemically modified SLA surface: a randomized pilot study. *Int J Oral Maxillofac Implants* 2007;22:755-760.

⁴ Lang NP, Salvi GE, Huynh-Ba G, Ivanovski S, Donos N, Bosshardt DD. Early osseointegration to hydrophilic and hydrophobic implant surfaces in humans. *Clin Oral Implants Res* 2011;22:349-356.

⁵ Ganeles J, Zöllner A, Jackowski J, ten Bruggenkate C, Beagle J, Guerra F. Immediate and early loading of Straumann implants with a chemically modified surface (SLActive) in the posterior mandible and maxilla: 1-year results from a prospective multicenter study. *Clin Oral Implants Res* 2008;19:1119-1128.

⁶ From single-tooth to fully edentulous

#